Multiplatform-based molecular subtypes of non-small-cell lung cancer

F. Chen, Y. Zhang, E. Parra, J. Rodriguez, C. Behrens, R. Akbani, Y. Lu, J. M. Kurie, D. L. Gibbons, Gordon Mills, I. I. Wistuba, C. J. Creighton

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Non-small-cell lung cancer (NSCLC) demonstrates remarkable molecular diversity. With the completion of The Cancer Genome Atlas (TCGA), there is opportunity for systematic analyses of the entire TCGA NSCLC cohort, including comparisons and contrasts between different disease subsets. On the basis of multidimensional and comprehensive molecular characterization (including DNA methylation and copy, and RNA and protein expression), 1023 NSCLC cases-519 from TCGA adenocarcinoma (AD) project and 504 from TCGA squamous cell carcinoma (SQCC) project-were classified using a 'cluster-of-clusters' analytic approach. Patterns from TCGA NSCLC subsets were examined in independent external databases, including the PROSPECT (Profiling of Resistance patterns and Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax) NSCLC data set. Nine genomic subtypes of NSCLC were identified, three within SQCC and six within AD. SQCC subtypes were associated with transcriptional targets of SOX2 or p63. One predominately AD subtype (with a large proportion of SQCC) shared molecular features with neuroendocrine tumors. Two AD subtypes manifested a CpG island methylator phenotype. Three AD subtypes showed high p38 and mTOR pathway activation. AD subtypes associated with low differentiation showed relatively worse prognosis. SQCC subtypes and two of the AD subtypes expressed cancer testis antigen genes, whereas three AD subtypes expressed several immune checkpoint genes including PDL1 and PDL2, corresponding with patterns of greater immune cell infiltration. Subtype associations for several immune-related markers-including PD1, PDL1, CD3 and CD8-were confirmed in the PROSPECT cohort using immunohistochemistry. NSCLC molecular subtypes have therapeutic implications and lend support to a personalized approach to NSCLC management based on molecular characterization.

Original languageEnglish (US)
Pages (from-to)1384-1393
Number of pages10
JournalOncogene
Volume36
Issue number10
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Adenocarcinoma
Atlases
Squamous Cell Carcinoma
Genome
Neoplasms
Thorax
CpG Islands
Neuroendocrine Tumors
Testicular Neoplasms
DNA Methylation
Genes
Biomarkers
Immunohistochemistry
Databases
RNA
Phenotype
Antigens
Proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Chen, F., Zhang, Y., Parra, E., Rodriguez, J., Behrens, C., Akbani, R., ... Creighton, C. J. (2017). Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene, 36(10), 1384-1393. https://doi.org/10.1038/onc.2016.303

Multiplatform-based molecular subtypes of non-small-cell lung cancer. / Chen, F.; Zhang, Y.; Parra, E.; Rodriguez, J.; Behrens, C.; Akbani, R.; Lu, Y.; Kurie, J. M.; Gibbons, D. L.; Mills, Gordon; Wistuba, I. I.; Creighton, C. J.

In: Oncogene, Vol. 36, No. 10, 01.03.2017, p. 1384-1393.

Research output: Contribution to journalArticle

Chen, F, Zhang, Y, Parra, E, Rodriguez, J, Behrens, C, Akbani, R, Lu, Y, Kurie, JM, Gibbons, DL, Mills, G, Wistuba, II & Creighton, CJ 2017, 'Multiplatform-based molecular subtypes of non-small-cell lung cancer', Oncogene, vol. 36, no. 10, pp. 1384-1393. https://doi.org/10.1038/onc.2016.303
Chen F, Zhang Y, Parra E, Rodriguez J, Behrens C, Akbani R et al. Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene. 2017 Mar 1;36(10):1384-1393. https://doi.org/10.1038/onc.2016.303
Chen, F. ; Zhang, Y. ; Parra, E. ; Rodriguez, J. ; Behrens, C. ; Akbani, R. ; Lu, Y. ; Kurie, J. M. ; Gibbons, D. L. ; Mills, Gordon ; Wistuba, I. I. ; Creighton, C. J. / Multiplatform-based molecular subtypes of non-small-cell lung cancer. In: Oncogene. 2017 ; Vol. 36, No. 10. pp. 1384-1393.
@article{ce7e1363033a4b28b8bfe03042a634dd,
title = "Multiplatform-based molecular subtypes of non-small-cell lung cancer",
abstract = "Non-small-cell lung cancer (NSCLC) demonstrates remarkable molecular diversity. With the completion of The Cancer Genome Atlas (TCGA), there is opportunity for systematic analyses of the entire TCGA NSCLC cohort, including comparisons and contrasts between different disease subsets. On the basis of multidimensional and comprehensive molecular characterization (including DNA methylation and copy, and RNA and protein expression), 1023 NSCLC cases-519 from TCGA adenocarcinoma (AD) project and 504 from TCGA squamous cell carcinoma (SQCC) project-were classified using a 'cluster-of-clusters' analytic approach. Patterns from TCGA NSCLC subsets were examined in independent external databases, including the PROSPECT (Profiling of Resistance patterns and Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax) NSCLC data set. Nine genomic subtypes of NSCLC were identified, three within SQCC and six within AD. SQCC subtypes were associated with transcriptional targets of SOX2 or p63. One predominately AD subtype (with a large proportion of SQCC) shared molecular features with neuroendocrine tumors. Two AD subtypes manifested a CpG island methylator phenotype. Three AD subtypes showed high p38 and mTOR pathway activation. AD subtypes associated with low differentiation showed relatively worse prognosis. SQCC subtypes and two of the AD subtypes expressed cancer testis antigen genes, whereas three AD subtypes expressed several immune checkpoint genes including PDL1 and PDL2, corresponding with patterns of greater immune cell infiltration. Subtype associations for several immune-related markers-including PD1, PDL1, CD3 and CD8-were confirmed in the PROSPECT cohort using immunohistochemistry. NSCLC molecular subtypes have therapeutic implications and lend support to a personalized approach to NSCLC management based on molecular characterization.",
author = "F. Chen and Y. Zhang and E. Parra and J. Rodriguez and C. Behrens and R. Akbani and Y. Lu and Kurie, {J. M.} and Gibbons, {D. L.} and Gordon Mills and Wistuba, {I. I.} and Creighton, {C. J.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1038/onc.2016.303",
language = "English (US)",
volume = "36",
pages = "1384--1393",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Multiplatform-based molecular subtypes of non-small-cell lung cancer

AU - Chen, F.

AU - Zhang, Y.

AU - Parra, E.

AU - Rodriguez, J.

AU - Behrens, C.

AU - Akbani, R.

AU - Lu, Y.

AU - Kurie, J. M.

AU - Gibbons, D. L.

AU - Mills, Gordon

AU - Wistuba, I. I.

AU - Creighton, C. J.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Non-small-cell lung cancer (NSCLC) demonstrates remarkable molecular diversity. With the completion of The Cancer Genome Atlas (TCGA), there is opportunity for systematic analyses of the entire TCGA NSCLC cohort, including comparisons and contrasts between different disease subsets. On the basis of multidimensional and comprehensive molecular characterization (including DNA methylation and copy, and RNA and protein expression), 1023 NSCLC cases-519 from TCGA adenocarcinoma (AD) project and 504 from TCGA squamous cell carcinoma (SQCC) project-were classified using a 'cluster-of-clusters' analytic approach. Patterns from TCGA NSCLC subsets were examined in independent external databases, including the PROSPECT (Profiling of Resistance patterns and Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax) NSCLC data set. Nine genomic subtypes of NSCLC were identified, three within SQCC and six within AD. SQCC subtypes were associated with transcriptional targets of SOX2 or p63. One predominately AD subtype (with a large proportion of SQCC) shared molecular features with neuroendocrine tumors. Two AD subtypes manifested a CpG island methylator phenotype. Three AD subtypes showed high p38 and mTOR pathway activation. AD subtypes associated with low differentiation showed relatively worse prognosis. SQCC subtypes and two of the AD subtypes expressed cancer testis antigen genes, whereas three AD subtypes expressed several immune checkpoint genes including PDL1 and PDL2, corresponding with patterns of greater immune cell infiltration. Subtype associations for several immune-related markers-including PD1, PDL1, CD3 and CD8-were confirmed in the PROSPECT cohort using immunohistochemistry. NSCLC molecular subtypes have therapeutic implications and lend support to a personalized approach to NSCLC management based on molecular characterization.

AB - Non-small-cell lung cancer (NSCLC) demonstrates remarkable molecular diversity. With the completion of The Cancer Genome Atlas (TCGA), there is opportunity for systematic analyses of the entire TCGA NSCLC cohort, including comparisons and contrasts between different disease subsets. On the basis of multidimensional and comprehensive molecular characterization (including DNA methylation and copy, and RNA and protein expression), 1023 NSCLC cases-519 from TCGA adenocarcinoma (AD) project and 504 from TCGA squamous cell carcinoma (SQCC) project-were classified using a 'cluster-of-clusters' analytic approach. Patterns from TCGA NSCLC subsets were examined in independent external databases, including the PROSPECT (Profiling of Resistance patterns and Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax) NSCLC data set. Nine genomic subtypes of NSCLC were identified, three within SQCC and six within AD. SQCC subtypes were associated with transcriptional targets of SOX2 or p63. One predominately AD subtype (with a large proportion of SQCC) shared molecular features with neuroendocrine tumors. Two AD subtypes manifested a CpG island methylator phenotype. Three AD subtypes showed high p38 and mTOR pathway activation. AD subtypes associated with low differentiation showed relatively worse prognosis. SQCC subtypes and two of the AD subtypes expressed cancer testis antigen genes, whereas three AD subtypes expressed several immune checkpoint genes including PDL1 and PDL2, corresponding with patterns of greater immune cell infiltration. Subtype associations for several immune-related markers-including PD1, PDL1, CD3 and CD8-were confirmed in the PROSPECT cohort using immunohistochemistry. NSCLC molecular subtypes have therapeutic implications and lend support to a personalized approach to NSCLC management based on molecular characterization.

UR - http://www.scopus.com/inward/record.url?scp=85027945046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027945046&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.303

DO - 10.1038/onc.2016.303

M3 - Article

C2 - 27775076

AN - SCOPUS:85027945046

VL - 36

SP - 1384

EP - 1393

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 10

ER -